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ABSTRACT 
Background: 
Decompensated Chronic Liver Disease is associated with disturbances 
in regulation of water balance leading on to abnormalities in serum sodium. 
Various studies have established a correlation between serum sodium levels 
and survival in these patients. Dilutional Hyponatremia due to impaired free 
water clearance is the most common dysnatremia while hypernatremia due to 
cathartic use has also been reported in few studies. The aim of this study was to 
study the serum sodium levels in patients with DCLD and to establish its 
significance. 
Methods: 
Data were collected from 97 patients admitted in medical wards. 
Patients were divided into groups based on serum sodium levels and the 
relevant parameters analyzed among the groups.  
Results: 
Among 97 patients, 42 (43.30%)had serum sodium levels ≥136 mEq/L, 
while 32(32.99%)had serum sodium levels between 131 and 135 mEq/L. 
23(23.71%) patients had serum sodium level ≤130. No patients had serum 
sodium levels greater than 145. Serum sodium levels was associated strongly 
with the severity of liver disease as assessed by Child Pugh and MELD score. 
Serum sodium ≤130 indicated the existence of Hepatic Encephalopathy (p 
value <0.0001), Hepatorenal Syndrome(p value <0.0001) and Spontaneous 
Bacterial Peritonitis(p value <0.0001). Patients with serum sodium less than 
130 mEq/L had increased frequency of complications than those with ≥136 
mEq/L. Patient with serum sodium levels ≤130 had increased mortality(30.4%; 
p value- 0.002) 
Conclusion: 
Hyponatremia is more common in DCLD and low serum sodium levels 
are associated with increased frequency of complications such as hepatic 
encephalopathy, hepatorenal syndrome, spontaneous bacterial peritonitis and 
GI bleeding. Lower serum sodium levels were associated with increased 
MELD CPS score and mortality indicating the inverse relationship between 
serum sodium levels and severity of the disease. 
Keywords: Hyponatremia, Hypernatremia, Decompensated Chronic 
Liver Disease. 
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INTRODUCTION 
 The normal range of serum sodium is 135-145 mEq/L. Its homeostasis is 
vital to the functioning of the cell. An imbalance in the regulation of total body 
water can lead to abnormal sodium levels. Decompensated chronic liver 
disease(DCLD) is associated with disturbance in water homeostasis leading to 
dysnatremias. 1-7 
 Hyponatremia is defined as concentration of sodium less than 135 
mEq/L. It occurs when there is excess of water in relation to sodium. It is the 
most common electrolyte disorder in hospitalized patients and more so in 
DCLD patients.6,7,8-15 A disturbance in total body water regulation leading to 
decreased clearance of solute free water and the consequent inability to match 
the urine output to the amount of water ingested leads to dilutional 
hyponatremia.  
 Hypernatremia is defined as concentration of sodium more than 145 
mEq/L. It is associated with high mortality rate. Hypernatremia, though 
uncommon compared to hyponatremia in DCLD patients, occurs due to use of 
osmotic cathartics and Upper Gastro Intestinal (UGI) bleeding. If present, it is 
associated with increased mortality.16 
 Recent studies have reported that lower serum sodium levels were 
associated with increased complications and mortality leading to incorporation 
of sodium in the MELD score.6,8,11,13-15  Hypernatremia when present is also 
associated with increased mortality. Therefore we undertook this study in our 
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tertiary hospital to study serum sodium levels in patients admitted with DCLD 
and to establish its significance. 
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AIMS AND OBJECTIVES 
1. To study serum sodium levels in patients with Decompensated 
Chronic Liver Disease and establish its significance. 
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REVIEW OF LITERATURE 
 A substance that dissociates into ions and acquire the capacity to 
conduct electricity is defined as Electrolyte. In the body, Sodium, Potassium, 
Magnesium and Calcium are the cations while Bicarbonate, Chloride and 
Phosphate are the anions. These electrolytes are involved in the metabolic 
activities and are essential to the normal functioning of the cell. 
 The concentration of various electrolytes in the body fluid is maintained 
within a narrow range. However the optimal concentrations in the extracellular 
and intracellular fluid differ. For example the concentration of sodium in 
extracellular fluid is 15 times more than in the intracellular fluid. Conversely 
the concentration of potassium within the cells is 30 times more than that 
present in the extracellular fluid.17 
COMPOSITION OF BODY FLUIDS: 
 The most abundant constituent in the body is water. It accounts for 50% 
of body weight in women and 60% in men. Water is distributed in two major 
compartments within the body. Total Body Water[TBW] is distributed as 
Intracellular Fluid [ICF] and Extracellular Fluid [ECF]. ICF constitutes 55-75% 
of TBW while ECF constitutes about 25-45%.(Figure 1) ECF is further divided 
into Interstitial (extravascular) and Plasma water (intravascular) in the ratio of 
3:1as shown in Table 1. Starling Forces i.e., balance between the hydrostatic 
pressure gradient and the oncotic pressure, determines the movement of fluid 
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across capillary walls between these two compartments. Lymphatic flow 
redistributes the fluid back into the intravascular compartment. 
 
TABLE 1: DISTRIBUTION OF FLUIDS FOR A 70 KG MAN 
COMPARTMENT VOLUME OF FLUID-40L % OF TBW 
INTRACELLULAR 24L 60% 
PLASMA 3.2L 8% 
INTERSTITIAL FLUID 11.2L 28% 
TRANSCELLULAR 
FLUID 1.6L 4% 
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            FIGURE 1: DISTRIBUTION OF TOTAL BODY WATER 
Osmolality expressed as milliosmoles/kilogram(mOsm/Kg), is the 
concentration of all the solutes in a fluid whereas Tonicity denotes the 
concentration of “effective” solutes that causes shift of fluid across body fluid 
compartments. Sodium(Na+) and its accompanying anions[chloride(Cl-) and 
bicarbonate(HCO3-)] constitute the major ECF particles while Potassium(K+) 
and organic phosphate esters (ATP, Phospholipid and Creatine Phosphate) 
form the major ICF osmoles. Solutes such as Urea do not cause shift of water 
across most membranes and are thus called as Ineffective Osmoles. The 
difference in composition of major solutes in ECF and ICF is illustrated in 
Table 2.  
7 
 
                                
INTRACELLULAR(mEq/L) SOLUTES EXTRACELLULAR(mEq/L) 
25 Na+ 140 
150 K+ 4.5 
2 Cl- 100 
6 HCO3- 25 
15 Mg+ 1.2 
0.01 Ca2+ 2.4 
50 PO42- 1.2 
 
TABLE 2: COMPOSITION OF MAJOR SOLUTES IN ICF AND 
ECF. 
SODIUM AND WATER  HOMEOSTASIS: 
The function and survival of each cell in the body depends on the 
maintenance of proper milieu. A key component to this maintenance of this 
milieu is the tonicity of ECF, which also acts as a significant determinant of 
composition of intracellular fluid. Most aspects of our physiology such as 
signalling pathways, neuronal depolarization, myocyte signalling etc., are 
dependent on the constancy of the ambient osmolarity. 
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 Serum Sodium concentration is a single most important factor in 
determining the extracellular tonicity. It has to be tightly regulated for the 
normal functioning of the cell. Correspondingly, significant variation in 
concentration of serum sodium are tolerated poorly and causes cellular 
dysfunction. Though there are wide variations in intake of water, ingestion of 
solutes and non-urinary water loss, serum sodium is kept in a narrow range as a 
result of strict balance between water intake and water output. This strict 
balance is achieved through regulation of urinary tonicity. 
 Total Body Water content is tightly regulated by various mechanisms in 
the kidney such that changes in total body water match the changes in Na+  and 
K+. The regulation of water intake is determined by Thirst control and water 
excretion by urinary dilution and concentration. Dysnatremias are usually the 
result of abnormalities in water balance. 
 To understand the pathogenesis of dysnatremias with respect to water 
balance requires knowledge of both sides of water balance equation. The body 
loses about 1100ml of water per day via stools, respiratory tract surfaces and 
from the skin surface. In addition kidneys excrete some amount of water as part 
of clearance of solutes. An individual ingesting a standard diet should excrete 
400 mOsm of electrolytes(sodium, potassium and their respective anions) and 
500 mOsm of urea(100 mOsm from diet and 400 mOsm from protein 
ingestion).The maximum urinary concentration attained in a normal individual 
is 1200 mOsm. Therefore, a minimum of 750 mL water should be excreted by 
the kidneys for for the excretion of 900 mOsm of solutes. 
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TABLE 3: MODE OF WATER LOSS FROM THE BODY 
MODE OF WATER LOSS VOLUME 
STOOL 200ML 
EVAPORATION AT SKIN 500ML 
RESPIRATORY TRACT SURFACES 400ML 
KIDNEYS 750ML 
 
Water ingested as liquids, taken as solid food and that produced as a 
result of metabolism comprise the intake side of water balance. Water 
consumed as solid food and produced from metabolism are fixed at 1200 ml, 
almost equal to that of fixed non-urinary losses. The remaining 650 ml of water 
should be ingested to equal the output of 1850 ml and stay in balance. 
 Water balance is easily maintained as long as the individual consumes 
this precise amount of water. However, the kidney can maintain this balance 
even when there is wide variation in the non renal water losses and intake. This 
is mainly attributed to the ability of the kidney to vary the concentration of 
urine depending on the abnormalities on either side of water balance. 
 If the total water ingested is more than that required for the excretion of 
solutes, the additional free water is excreted by dilution of urine. When an 
individual consuming normal amount of water develops increased loss of water 
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through diarrhea, increased sweating  etc., the balance is maintained by the 
concentration of urine by the kidney and thirst stimulation. 
DILUTING AND CONCENTRATING MECHANISMS OF 
NEPHRON: 
Proximal Convoluted Tubule: (PCT) 
Distal Nephron is responsible for tight control of water balance. 
Adequate tubular fluid must reach the distal segment for this tight regulation to 
occur. The proximal convoluted tubular epithelium is water permeable and 
70% of the filtrate is reabsorbed isotonically, under normal conditions. The 
remaining 30% of filtrate that passes to loop of Henle is essential for the 
development of medullary interstitial tonicity gradient. The medullary tonicity 
gradient is essential for the overall maintenance of water balance. So, any 
decrease in the volume of fluid leaving the PCT and entering the loop of Henle 
will ultimately interfere with the control of water balance by altering the 
medullary tonicity gradient. This state of decreased delivery to distal segment 
occurs when glomerular filtration is reduced or the reabsorption in PCT is 
increased. This combination occurs in conditions causing volume depletion and 
poor renal perfusion. 
The Loop of Henle: 
 Water is passively reabsorbed through the aquaporin-1 water channel in 
the descending limb of loop of Henle driven by the increased medullary 
11 
 
hypertonicity. This shift of water and variable solute addition results in the 
tubular filtrate reaching its peak osmolarity of 1200 mOsm/L as it enters the 
ascending limb. In the thin ascending limb, sodium reabsorption is passive 
while in the water impermeable thick ascending limb Na+/K+/2Cl-  
cotransporters aid in the reabsorption of sodium, potassium and chloride. This 
causes the tubular fluid to reach an osmolarity nadir of 100 mOsm/L, which 
enters the distal tubule.  
The solute reabsorption and water impermeability in the ascending limb 
not only  dilutes the tubular fluid but also generates a gradient of tonicity in the 
medulla, with higher tonicities in the deeper medulla. This medullary tonicity 
gradient  is essential for the fine control of water balance exerted by AVP in 
the distal nephron. The medullary hypertonicity gradient not only depends on 
the adequate GFR and the amount of reabsorption at Proximal Convoluted 
Tubule but also on the upregulated blood flow in the vasa rectae at the Loop of 
Henle.  
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FIGURE 2: MECHANISM OF URINARY DILUTION 
Distal Tubule and Collecting Duct: 
The hypoosmotic fluid from loop of Henle reaches the collecting duct. 
The collecting duct descends through progressively increasing hypertonic 
medullary interstitium. The collecting duct is the region where fine control over 
water regulation is exerted. The important factor that determines the water 
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clearance and urine osmolarity at this point is Arginine Vasopressin(AVP). 
Knowledge about the action and regulation of AVP is important to understand 
the mechanism of water balance and the pathophysiology of dysnatremia. 
ARGININE VASOPRESSIN: (AVP) 
It is produced in the hypothalamus and gets stored as granules in the 
posterior pituitary. It is released in response to either osmotic or non-osmotic 
stimuli. The osmoreceptor cells in the Organum Vasculosum of the Lamina 
Terminalis(OVLT) and the subfornical organ mediates the osmotic trigger for 
AVP release. ECF osmolarity is sensed by these cells by way of cellular 
swelling and via their projections to anterior hypothalamus, they activate TRV4 
channels which trigger AVP release. As little as 1% increase in ECF osmolarity 
is suffice to cause AVP release and 1% decrease in ECF osmolarity results in 
complete AVP suppression.  
 The relationship between serum sodium and serum osmolarity is well 
established. AVP levels are undetectable in plasma when serum sodium is 
below 135 mEq/L. When the levels reach 140 mEq/L AVP levels reach 5 
pg/ml. AVP helps in maintaining serum osmolarity and serum sodium 
concentration within normal range. (Figure 3) 
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FIGURE 3: RELATIONSHIP BETWEEN OSMOLALITY AND 
VASOPRESSIN SECRETION 
There are various non osmotic stimuli for AVP release. Most important 
among them are decreased intravascular volume or blood pressure(BP). 
Intravascular volume is detected by the venous baroreceptors in atria and 
arterial baroreceptors in carotid arteries and aorta. Together these receptors 
sense a decrease in intravascular volume and BP; sends afferent signals via 
Vagus and Glossopharyngeal nerves to stimulate AVP release. 7% decrease in 
intravascular volume is suffice to stimulate AVP release.  
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Since this stimulus is important in defense against circulatory collapse, 
it is stronger than the osmotic stimuli. Other non-osmotic stimuli include 
hypoglycemia, nausea, emotional stress and pain.  
AVP ACTION ON KIDNEY: 
The collecting duct is relatively water impermeable in the absence of 
AVP and will allow the hypotonic fluid to be excreted as dilute urine without 
significant tonicity changes. The presence of AVP will cause a dramatic change 
in the tonicity of urine.  
V2 receptors are present on the basolateral membrane of collecting duct 
principal cells. AVP binds to these receptors and causes a translocation of 
Aquaporin 2(AQP2) water channels to the luminal membrane via cyclic AMP 
pathway3. This increases water permeability of collecting duct which causes 
passive water reabsorption along the concentration gradient into the hypertonic 
medullary interstitium. This action of AVP occurs within minutes and exerts 
control over short term regulation of water balance. When plasma AVP is 
elevated in a sustained manner, it causes increased expression of AQP2 and 
more AQP2 channels are available on the luminal side to allow maximal water 
permeability in the collecting duct. This long term regulation has implications 
in the hyponatremias that occur with edematous disorders. 
16 
 
 
 
FIGURE 4: MECHANISM OF ACTION OF AVP 
As AVP decreases urinary free water clearance, it causes dilution of 
high serum sodium concentration and returns osmolarity of serum to normal 
range. This causes feedback inhibition of AVP release from pituitary. The 
feedback inhibition also occurs via the improvement of any decreased 
intravascular volume or BP following water reabsorption, that might have 
contributed to the non-osmotic trigger for AVP release.(Figure 5) 
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FIGURE 5: FEEDBACK INHIBITION OF VASOPRESSIN 
SECRETION 
THIRST CONTROL: 
To understand water balance physiology, both the water intake and 
output side of water balance must be appreciated. Therefore it is prudent to 
understand thirst regulation that controls water intake. 
To begin with, hypertonicity not only stimulates AVP release but also 
the thirst as well. The consequent water intake together with AVP release 
restores normal tonicity. However thirst control is less sensitive than AVP in 
18 
 
regulating plasma osmolarity. Also, thirst regulation is complicated by other 
factors. 
The plasma osmolarity required for thirst stimulation is approximately 
10 mOsm higher than that required for AVP release4.(Figure 6) Therefore, to 
stimulate thirst 2-3% increase in osmolarity is required compared with 1% 
increase for AVP release.  
 
  FIGURE 6: THIRST STIMULATION 
The osmotic set point for stimulation of thirst occurs at the point when 
the urine is maximally concentrated by the action of AVP. In other words, 
water intake is increased only when the kidneys ability to retain water is at its 
maximum. Also thirst is influenced by other factors such as mouth dryness, 
hypovolemia, hypotension etc.,18,19. It can be suppressed by mechanoreceptors 
in oropharyngeal area when they sense fluid intake20. 
19 
 
 In contrast to AVP’s minute to minute water regulation, thirst 
regulation that acts via gastrointestinal absorption of water, takes upto one hour 
for the correction of osmolarity. Thus thirst regulation acts like a second line of 
defense in water balance. Transient suppression of AVP and thirst occurs when 
there is overcorrection with rapid fluid intake, which prevents drop in serum 
osmolarity. 
Thirst control and regulation of concentration of urine helps in the 
maintenance of water balance despite wide variations in water intake and 
output. When this balance is disrupted, dysnatremias occur.  
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HYPONATREMIA 
Hyponatremia is defined as plasma concentration of sodium less than 
135mEq/L21. Hyponatremia is a common occurrence in patients getting 
admitted to hospitals especially in Intensive Care Unit. It has been found that 
15-30% of patients have low serum sodium concentration at some point during 
admission22. It usually results when kidney is unable to excrete a water load or 
excess intake of water.  
 Hyponatremia usually occurs when there is an increase in AVP or 
increase in renal sensitivity to AVP, in addition to excess free water intake7. 
Hence, this disorder can occur when there is increase in TBW, or decrease in 
solutes or combination of both. In most cases multiple mechanisms are operant. 
In assessing a patient with hyponatremia, the first step is to ensure that the 
decrease in serum sodium is due to a hypoosmotic state and not due to 
pseudohyponatremia or translocational hyponatremia.  
Pseudo-hyponatremia: 
It is also called normo-osmolal or isotonic hyponatremia. It is due to 
increase in triglycerides or increase in plasma proteins in conditions like 
Multiple Myeloma. In normal individuals, plasma water accounts for 93% of 
plasma volume and proteins, fats contribute to the remaining 7%. In 
hypertriglyceridemia or hyperproteinemia, the contribution of plasma water to 
plasma volume is reduced to 80%23,24. Plasma osmolality and plasma water 
sodium concentration remain unchanged. However, the measured sodium 
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concentration is reduced because of the lowered plasma water concentration in 
the sample.  
Translocational Hyponatremia: 
It is also called hypertonic or redistributive hyponatremia. It is due to 
the presence of glucose or mannitol, that are osmotically active solutes25. The 
presence of significant amounts of these unmeasured solutes in plasma hinders 
the calculation of accurate plasma osmolality warranting direct measurement.  
FIGURE 7: TYPES OF HYPONATREMIA 
   
After excluding pseudohyponatremia and the presence of osmotically 
active solutes in ECF, assessment of ECF volume provides a useful way of 
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classifying true hyponatremia(hypoosmolal hyponatremia) as it can be 
associated with low, normal or increased total body sodium.  
1. Hyponatremia with depletion of ECF volume – Hypovolemic 
Hyponatremia 
2. Hyponatremia with excess ECF volume – Hypervolemic Hyponatremia 
3. Hyponatremia with normal ECF volume – Euvolemic Hyponatremia 
FIGURE 8: CLASSIFICATION OF HYPONATREMIA BASED 
ON ECF VOLUME STATUS 
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HYPOVOLEMIC HYPONATREMIA: 
It arises when the decrease in total body sodium is out of proportion to 
decrease in total body water. AVP release is triggered by the decrease in 
intravascular volume and fall in blood pressure. This non osmotic stimuli 
overrides the suppression of AVP release by osmoreceptors that detect 
hypoosmolality, as described in the “Law of the Circulating Volume”. It states 
that the preservation of blood volume and maintenance of blood pressure takes 
precedence over maintenance of tonicity. 
AVP acts on the V1A receptors in blood vessels and V2 receptors in 
kidney to maintain blood pressure and increase water absorption respectively. 
V2 receptor activation can lead to hyponatremia if there is increased free water 
intake. 
Table 4 shows the causes of Hypovolemic hyponatremia classified on 
the basis of U[Na]. 
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                     U[Na] <10                            U[Na] >20 
Extra Renal Causes 
 Diarrhea 
 Vomiting 
 Third Space 
- Burns 
- Pancreatitis 
- Trauma  
- Muscle 
Renal Causes 
 Diuretic Excess 
 Mineralocoticoid Excess 
 Salt Losing Nephritis 
 Bicarbonaturia(Renal Tubular 
Acidosis, Metabolic Alkalosis) 
 Ketonuria 
 Osmotic Diuresis 
 
TABLE 4: CAUSES OF HYPONATREMIA BASED ON UNa 
HYPERVOLEMIC HYPONATREMIA: 
It is a condition in which both total body sodium and water are 
increased, but the retention of water is out of proportion to the retention of 
sodium. This is mostly seen with disorders with edematous states such as 
cirrhosis, heart failure and the severity of hyponatremia is thought to serve as a 
marker of severity as well as prognostic indicator of the underlying disease. 
The mechanism by which hyponatremia occurs in these disorders can be 
attributed to the hormonal and intra-renal changes related to low Effective 
Arterial Blood Volume(EABV)26. 
Hyponatremia is seen in patients with advanced Congestive Heart 
Failure(CHF)27,28. It is an indicator of poor prognosis29. Cardiopulmonary 
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congestion and decreased left sided output results in underfilling of arteries. 
This is sensed by the mechanoreceptors present in left ventricle, aortic arch, 
carotid sinus and afferent arterioles in  kidney30. Activation of these receptors 
leads to increased sympathetic outflow, activation of renin-angiotensin-
aldosterone system which causes a decrease in GFR and increase in proximal 
tubular reabsorption. This leads to decreased delivery of water to distal nephron 
and inability to achieve adequate medullary interstitial tonicity gradient, thus 
causing an impairment of free water clearance. Activation of mechanoreceptors 
also causes non osmotic release of AVP and thirst stimulation. AVP release 
and increased free water intake due to thirst combine to produce hyponatremia. 
Also, expression of AQP2 has been shown to be increased causing greater 
absorption of water in the presence of AVP in animal studies with advanced 
CHF31.   
Cirrhosis is another condition in which hypervolemic hyponatremia can 
be seen. Vasodilation in splanchnic and peripheral circulation leads to low 
EABV. This low EABV, like in CHF leads to hyponatremia.  
Hypervolemic hyponatremia has been reported in Nephrotic syndrome 
also, but their presence is inconsistent and unrelated to the severity of disease. 
Hypervolemic hyponatremia has also been reported in patients with renal 
failure(either acute or chronic)32,33. Recent studies have showed a 15% 
prevalence of hyponatremia in chronic kidney disease(CKD) patients.  
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EUVOLEMIC HYPONATREMIA: 
This results when there is an increase in total body water without change 
in the level of total body sodium. This type of hyponatremia is encountered 
mostly in hospitalized patients32 and attributed to various causes that has a 
common mechanism- the release of AVP is unregulated and unprovoked by 
either osmotic or non-osmotic factors. Syndrome of Inappropriate Anti-
Diuretic Hormone(SIADH) is the most well recognized cause of euvolemic 
hyponatremia. It is the most common etiology of hyponatremia34. Table 5 
shows other causes of euvolemic hyponatremia. 
TABLE 5: CAUSES OF EUVOLEMIC HYPONATREMIA 
               URINE Na >20 mEq/L              URINE Na < 20 mEq/L 
 SIADH 
 Glucocorticoid deficiency 
 Hypothyroidism 
 Drugs  
 Primary polydipsia 
 Beer potomania 
 Exercise induced 
 
SYMPTOMS: 
Signs and symptoms of hyponatremia varies with the rate at which the 
serum sodium concentration declines and the age of the patient. Usually, young 
patients tolerate a specific level of hyponatremia better than elder patients. 
However, sudden onset of hyponatremia in a previously healthy adult may 
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cause severe neurologic signs and symptoms such as altered sensorium, 
convulsions and even death, though the serum sodium level is only between 
125-130 mEq/L.  
The severe clinical manifestations to sudden decline in serum sodium 
can be attributed to the inability of the brain cells to extrude osmotically active 
particles in a short time which can lead to brain swelling. However this 
protective mechanism becomes operant in chronic hyponatremia that an elderly 
person can present with minimal signs or symptoms even when the serum 
sodium level is around 110 mEq/L. Patients with chronic hyponatremia may be 
asymptomatic or present with lethargy, anorexia, nausea, muscle cramps, 
frequent falls or gait disturbances. 
DIAGNOSIS: 
History and Examination: 
History and physical examination should be done in a way to identify 
findings that are typical for a specific cause of hyponatremia35,36. 
 History of volume loss such as diarrhea, vomiting with signs such 
as orthostatic hypotension, loss of skin turgor, dry mucous 
membrane 
 Signs of volume overload in the form of peripheral edema, 
ascites due to cirrhosis, cardiac failure and renal failure 
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 To look for any one of the causes of SIADH such as CNS disease 
or small cell carcinoma of lung 
 Prolonged intake of drugs that are known to cause hyponatremia 
 Symptoms and signs indicative of hypothyroidism or adrenal 
insufficiency 
Although history and examination can give a clue to the diagnosis it is 
prudent to establish the diagnosis with laboratory investigations. 
LABORATORY INVESTIGATIONS: 
1. Measurement of Serum Sodium: 
Ideally done by ion specific electrode(ISE) using direct 
potentiometry to prevent Pseudohyponatremia. However most 
laboratories use ISE with indirect potentiometry  in which plasma 
sample is diluted before measurement. 
2. Serum Osmolality: 
Most patients have a serum osmolality less than 275mOsm/L. It 
helps in ruling out Pseudohyponatremia and hyperosmolar 
hyponatremia. 
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3. Urine Osmolality: 
It is used to distinguish between hyponatremia with normal water 
excretion and impaired water excretion. 
TABLE 6: CAUSES OF HYPONATREMIA BASED ON URINE 
OSMOLALITY 
    URINE OSMOLALITY         
>150 mOsm/Kg 
   URINE OSMOLALITY         <150 
mOsm/Kg 
 Hypovolemic hyponatremia 
 Cerebral salt wasting 
 Salt depletion 
 Euvolemic hyponatremia with 
high urine Na 
 Adrenal insufficiency 
 SIADH 
 Euvolemic hyponatremia 
 Hypovolemic hyponatremia 
 Acute diuretic use 
 Primary polydipsia 
 Beer potomania 
 Exercise induced hyponatremia 
 SIADH (reset osmostat variety) 
 
4. Urine Sodium Concentration: 
It is used to differentiate between renal and extrarenal loss of 
sodium in hypovolemic hyponatremia. In patients with normal handling 
of electrolytes by the kidney, the appropriate response to hypovolemia is  
to increase tubular reabsorption of sodium such that Urine Na+ is less 
than 10 mEq/L. If urine Na+ is more than 20 mEq/L, it implies either 
euvolemia as in SIADH or hypovolemic hyponatremia with renal salt 
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wasting. The latter condition may arise from dysfunctional tubular 
transport due to diuretics, hypoaldosteronism or intrinsic renal disease. 
5. Urine to Serum electrolyte ratio: 
It is calculated by dividing the sum of urine sodium and 
potassium concentrations by the serum sodium concentration. 
 If it is <0.5, it implies more of electrolyte free water in urine and 
fluid correction alone is enough in treatment 
 If it is >1, it implies urine is hypertonic than serum and in 
addition to fluid restriction, other pharmacologic measures are 
needed in treatment37. 
6. Fraction excretion of Sodium: [FENa] 
It is better than urine sodium in providing an accurate assessment of 
volume status because it corrects the effect of variations of urine volume 
that can have an impact on urine sodium. The cut-off for patients with 
hyponatremia and normal renal function is 0.1%. 
 If FENa < 0.1%, it indicates hypovolemic hyponatremia 
 If FENa > 0.1%, it indicates hypervolemic or euvolemic hyponatremia 
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7. Serum Uric Acid and Urea: 
Low serum uric acid and urea: 
i. SIADH 
ii. Hypopituitarism 
iii. Hypervolemia 
iv. Thiazide diuretic induced hyponatremia 
Normal serum uric acid and urea 
i. In hypovolemia, the serum uric acid and urea levels may 
be normal or high. 
8. Acid Base and Potassium Balance: 
It may be helpful in some patients38. 
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TABLE 7: CAUSE OF HYPONATREMIA BASED ON ACID BASE 
STATUS AND POTASSIUM IMBALANCE 
ACID BASE 
IMBALANCE 
POTASSIUM 
IMBALANCE 
CAUSES 
Metabolic alkalosis Hypokalemia Diuretic use or vomiting 
Metabolic acidosis Hypokalemia Diarrhea or laxative 
abuse 
Metabolic acidosis Hyperkalemia Primary adrenal 
insufficiency in patients 
without renal failure 
Normal Normal SIADH 
Mild metabolic alkalosis Normal Hypopituitarism 
 
9. Saline Infusion: 
If diagnosis is doubtful, one can administer 0.9% NaCl with serum 
sodium monitoring and follow up at 6 hours. Patients with hypovolemic 
hyponatremia usually improve with 0.9% NaCl administration while 
hyponatremia due to SIADH does not improve or may get worsened. 
OTHER INVESTIGATIONS: 
Thyroid Profile, CT/MRI Brain/Chest, ACTH and ACTH stimulation 
tests can be done depending on individual patients’ presentation. 
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TREATMENT: 
 Treatment depends on 
1. Volume status 
2. Duration of hyponatremia (Acute- Less than 48 hours; Chronic- More 
than 48 hours) 
3. Presence or absence of symptoms 
4. Cause of hyponatremia35,39,40,41 
EUVOLEMIC HYPONATREMIA: 
 Acute Hyponatremia: 
Rapid correction is necessary as there is increased risk of brain 
herniation. It is common in patients with primary polydipsia, marathon 
runners and ecstasy users. Recent recommendations suggest that a bolus 
of 100ml 3%NaCl be given over 10 mins. It can be repeated upto 3 
times till acute symptoms subside. A total of 4-6 mmol/L correction is 
needed to prevent herniation of brain. For patients with mild to moderate 
symptoms and low risk of brain herniation, 3% NaCl infusion can be 
given at the rate of 0.5-2ml/kg/hour21. 
 Chronic Hyponatremia: 
Chronic hyponatremia that presents with seizures or confusion 
and severe(serum concentration less than 125 mEq/L) must be treated 
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with 3% NaCl as in acute hyponatremia with a goal of 4-6 mmol/L rise 
above baseline. 
Patients with mild symptoms such as dizziness, gait disturbances 
can be treated less aggressively. 
o Fluid restriction when the urine to serum electrolytes is 
<0.5 
o When the urine to serum electrolytes ratio is >1, in 
addition to fluid restriction, pharmacotherapy with salt 
tablets and loop diuretic can be used. 
o An alternative approach is to start with vasopressin 
antagonist without fluid restriction. 
Rate of Correction: 
 In chronic hyponatremia, the brain undergoes adaptation and 
hence the risk of herniation of brain is low. Hence, gradual correction is 
suffice to correct hyponatremia. Rapid correction may lead to Osmotic 
Demyelination Syndrome(ODS). Patients with serum sodium 
<120mEq/l, liver diseases, hypokalemia, alcoholism, malnutrition etc 
are at risk for ODS.  
 In patients with low risk of ODS, 4-8 mmol/day rise is suffice to 
correct symptoms of hyponatremia with a maximum of 10-12 
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mmol/day. In patients with high risk of ODS, 4-6 mmol/day rise is 
considered enough with a maximum of 8 mmol/day. 
OSMOTIC DEMYELINATION SYNDROME: 
 It is a rare and severe disorder that can be irreversible at times. It 
presents with locked in state quadriparesis with preserved vertical eye 
movements. It was previously called Central Pontine Myelinolysis, but the 
name was changed as the demyelination involves other areas also. Though 
adaptations in chronic hyponatremia prevents brain swelling, it also increases 
risk of ODS from rapid correction. Recent studies have revealed that ODS can 
be reversed by lowering sodium and treatment with Desmopressin. 
ASSESSMENT OF EFFICACY OF INITIAL THERAPY: 
 Increase in serum sodium following administration of one litre of a 
solution to a patient with hyponatremia can be calculated by Adrogue Madias 
formula. 
 Increase in Serum Na = (Infusate Na- Serum Na) / TBW + 1, 
where, TBW – Total Body Water is calculated from lean body weight. 
Potassium, when added to the solution should also be included(“Infusate Na + 
K”)as treatment of concurrent hypokalemia can increase the serum sodium 
concentration. Infusate Na for various solutions is given in table 8. 
 
36 
 
SOLUTION INFUSATE Na mEq/L 
5% NaCl 855 
3% NaCl 513 
0.9% NaCl 154 
Ringer Lactate 130 
 
TABLE 8: SODIUM CONTAINING SOLUTIONS AND THEIR 
CONCENTRATION 
This formula has limitations and cannot predict the magnitude of change 
in serum sodium accurately. Present guidelines do not recommend the use of 
formula. Rather, it is predicted that 1ml/kg of 3% NaCl raises the serum Na by 
1 mEq/L. 
HYPOVOLEMIC HYPONATREMIA: 
Sodium Chloride as 0.9% NaCl is usually administered as it can correct 
the volume deficit. 3% NaCl is not indicated. 0.9% NaCl acts by two 
mechanisms. It improves the serum sodium by 1 mEq/L for every 1 litre of 
fluid administered and by correcting hypovolemia, decreases the stimulus for 
release of AVP. Potassium should also be monitored and corrected. 
Hyponatremia caused by thiazide diuretics is usually chronic and hence rapid 
correction should be avoided in view of ODS. These patients are more prone 
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for recurrence and should not be restarted on Thiazides. Vaptans are not 
indicated for hypovolemic hyponatremia. 
HYPERVOLEMIC HYPONATREMIA: 
Hypervolemic hyponatremia is seen in CHF and Cirrhosis. 3% NaCl is 
usually contraindicated for chronic treatment in edematous patients. It can be 
given in patients with acute hyponatremia as discussed above. 
 Water restriction remains the mainstay of treatment. Fluid restriction 
less than 750 ml to be followed by cirrhotic patients which is difficult. The 
cornerstone for therapy in hypervolemic hyponatremia is Loop Diuretics. 
Terlipressin, V1a receptor agonist is used in patients with hepatorenal 
syndrome. 
VASOPRESSIN RECEPTOR ANTAGONISTS: (VAPTANS) 
They are antagonists of vasopressin receptors. There are multiple 
receptors for vasopressin: V1A, V1B, V2. V1A causes vasoconstriction; , V1B 
causes ACTH release and V2 receptors cause antidiuresis. Vaptans cause water 
loss without alterations in sodium and potassium excretion. They do not cause 
renal impairment and do not stimulate neurohormonal system. Thus they act as 
the appropriate physiological approach to hyponatremia and fluid restriction is 
not required. They are marketed as oral or iv formulations. Non Selective 
vaptans act on all the three receptors, while selective vaptans act on specific 
receptors. 
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NON SELECTIVE(V1 & V2) CONIVAPTAN(I.V.) 
SELECTIVE V1A RECPTOR ANTAGONIST RELCOVAPTAN 
SELECTIVE V1B RECPTOR ANTAGONIST NELIVAPTAN 
SELECTIVE V2 RECPTOR ANTAGONIST LIXIVAPTAN, 
MOXAVAPTAN, 
SATAVAPTAN, 
TOLVAPTAN 
 
TABLE 9: CLASSIFICATION OF VAPTANS 
Tolvaptan and Conivaptan are available in India. 
Vaptans in Euvolemic Hyponatremia: 
 Vaptans are usually not used as a single agent in hyponatremic 
emergencies. Sometimes it can be used as an adjunctive therapy to 3% NaCl. 
Vaptans are used in chronic hyponatremia in addition to fluid restriction and 
sodium chloride administration42,43. 
Vaptans in Hypervolemic Hyponatremia: 
 Vaptans can be used in patients with CHF for correction of fluid 
overload and/or hyponatremia after initial trials with water restriction and fluid 
overload. Various studies have demonstrated hyponatemia in CHF is associated 
with increased mortality and re-admission rates. CHF is associated with 
chronic hyponatremia and thus should be corrected till serum Na levels become 
normal so that dosage of diuretics can be optimized.  
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 Vaptans can be used in patients with decompensated liver disease for 
management of hyponatremia after initial treatment with fluid restriction and 
diuretics. Tolvaptan was found to be hepatotoxic and hence USFDA limited  
their use to end stage liver disease patients where liver transplantation is 
imminent and correction of hyponatremia before surgery will decrease the risk 
of ODS postoperatively. Although studies have shown that vaptans help in 
improving serum sodium levels, there was no difference between vaptans and 
control groups with regard to mortality and complications of decompensated 
liver disease.  
Contraindications to Vaptans: 
 Vaptans are contraindicated in hypovolemic hyponatremia. They should 
not be used in euvolemic hyponatremia patients caused by emetic stimuli and 
secondary adrenal insufficiency. They are found to be ineffective in SIADH 
caused due to activating mutation of V2 receptor. In cerebral salt wasting and 
psychogenic polydipsia, where AVP levels are inappropriate, Vaptans are 
found to be ineffective. 
Adverse Effects: 
 Thirst, Orthostatic Hypotension, Dryness of mouth and Encephalopathy. 
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HYPERNATREMIA 
 Hypernatremia defined as a serum concentration of sodium more than 
145 mEq/L, occurs in about 1% of hospitalized patients44 and 7% of patients 
who are admitted in intensive care unit45. Though it is uncommon to be a 
primary cause for death, as much as 40% mortality has been reported in 
patients with hypernatremia.  
PATHOPHYSIOLOGY: 
Hypernatremia results from disequilibrium of water balance in which 
there is excess of Na in relation to water in ECF. Mostly it results from water 
deficit and at times due to sodium overload. Water deficit results from 
inadequate intake or excessive water loss. Patients with appropriate thirst 
response and access to fluid intake compensate to these changes. 
As a result of increased sodium in the ECF, the osmotic load increases 
and this is compensated by loss of water from inside the cells. This causes 
shrinkage of the cells due to dehydration. The cells respond to this shrinkage by 
transporting solutes across the cell membrane, thus altering the resting 
potentials of electrically active cell membrane. To avoid structural damage and 
restore the cell volume, organic solutes are generated intracellularly.  
The effects of cellular dehydration and shrinkage with altered membrane 
potentials are primarily manifested in the CNS leading to ineffective 
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functioning. When shrinkage of neuron is severe, it leads to stretching and may 
cause rupture of bridging veins. 
Infants, elderly and debilitated patients are dependent on the caregiver 
for providing water. They are more prone for hypernatremia. Essential or 
adipsic hypernatremia occurs as a result of congenital or acquired defect of 
osmoreceptors present in hypothalamus. This leads to dysregulation of 
vasopressin release and thirst response leading to hypernatremia  with 
hypovolemia. 
Renal water loss occurs as a result of inability of the distal tubule to 
concentrate urine. This may result from failure of vasopressin action which 
leads to defective reabsorption of water. It can be due to, 
1. Inadequate Pituitary Secretion -  Central Diabetes Insipidus 
2. Resistance at the level of receptors – Nephrogenic Diabetes Insipidus 
These patients excrete excess amount of dilute urine and do not develop 
hypernatremia as long as they can maintain increased water intake to 
compensate their losses. Another common cause for excess loss of water 
through renal system is osmotic diuresis. This can be secondary to 
hyperglycemia, mannitol, excess urea and post-obstructive diuresis.  
Extra renal fluid loss can occur in the setting of fever, severe burns, 
exposure to heat, vigorous exercise and mechanical ventilation. Diarrhea is the 
leading cause of hypernatremia due to gastrointestinal pathology. Osmotic 
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diarrhea is more likely to cause hypernatremia than secretory diarrhea. Osmotic 
diarrhea and viral gastroenteritis produce stools with Na+ and K+ < 100 mM 
thus causing hypovolemia and hypernatremia. Secretory diarrhea produces 
isotonic stools and cause hypovolemic hyponatremia. 
Sodium excess due to use of intravenous fluids(0.9% NaCl) to correct 
insensible water loss can lead to hypernatremia. It can also be seen after 
sodium bicarbonate administration in metabolic acidosis, use of high sodium 
dialysate and intrauterine instillation of hypertonic saline for pregnancy 
termination. 
 
FIGURE 9: APPROACH TO HYPERNATREMIA 
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CLINICAL FEATURES: 
 Patients present with non specific symptoms that are predominantly 
neurological. They include lethargy, coma and seizures. Hypernatremic 
hypovolemia can precipitate venous sinus thrombosis. Shrinkage of brain due 
to hypernatremia can lead on to tearing of blood vessels to cause hemorrhage. 
 While examining the patient it is prudent to assess fluid volume status to 
categorize the etiology of hyponatremia. Signs of hypovolemia such as 
orthostatic hypotension, tachycardia should be looked for. Since these patients 
usually present with neurologic manifestation, it is important that complete 
neurologic examination be done. 
LABORATORY INVESTIGATIONS: 
When serum sodium is found to be high, one should obtain urine 
osmolality and sodium levels. Serum glucose levels should be checked to 
rule out osmotic diuresis.  
 If urine osmolality is high, the concentrating ability of the kidney is 
normal and extrarenal loss of fluid should be suspected. Normal urine 
osmolality is associated with osmotic diuresis. 
 In case of hypotonic urine with polyuria, DI should be suspected.  
CT or MRI of the Brain should be done to rule out hemorrhage or 
venous thrombosis. Water deprivation test and ADH stimulation test should be 
done to evaluate for Diabetes Insipidus. 
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TREATMENT: 
 The treatment of hypernatremia patients involve two steps. 
1. Correction of plasma tonicity 
2. Diagnosis and treatment of underlying disorder 
It should be remembered that hypernatremia should not be corrected at a 
rate more than 1mEq/L per hour. Fluid deficit should be calculated by, 
Water Deficit = Total Body Water*([Serum Na/140]-1) 
The change in serum sodium can be estimated by Adrogue-Madias 
formula. 
Change in Serum Na = (Infusate Na- Serum Na) / TBW + 1 
In hemodynamically unstable patients with hypovolemic hypernatremia, 
correction of vital signs with isotonic saline should be done before correcting 
free water deficits with hypotonic fluids. Euvolemic hypernatremia should be 
corrected with hypotonic fluids, either intravenously(dextrose 5% in 
water[D5W] or half isotonic sodium chloride) or orally. Hypervolemic 
hypernatremia should be treated with D5W to remove excess sodium. In central 
DI, desmopressin increases cellular permeability of collecting tubules and 
promotes reabsorption of water. It has been advocated for long term therapy in 
central DI. Patients with Nephrogenic DI must be taught to avoid salt and take 
large amounts of water. The underlying cause of hypernatremia should be 
found and treated. 
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LIVER 
Adult liver, weighing about 1.4-1.6 kg and contributing to 1.5-2.5% of 
lean body mass, is the largest internal organ in the human body. It performs 
various essential functions such as synthesis of plasma proteins; detoxification 
of endogenous and exogenous toxic metabolites; balancing the metabolism of 
carbohydrates, proteins and fats; secretion of bile etc., as shown in figure. 
FIGURE 10: FUNCTIONS OF LIVER 
 
DECOMPENSATED CHRONIC LIVER DISEASE: 
Chronic liver disease indicates a disease of the liver that causes 
progressive destruction and regeneration of its parenchyma leading on to 
fibrosis and cirrhosis. Chronic liver disease is said to be present when the 
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disease process lasts for six months. It is important for the clinicians to 
differentiate patients of chronic liver disease into those who have compensated 
liver function and those who have decompensated liver function. 
 Patients with chronic liver disease can present with decompensation in 
any one of the following forms. 
1. Ascites 
2. Variceal Bleed 
3. Hepatic Encephalopathy 
4. Hepato Renal Syndrome 
5. Coagulopathy 
6. Hepatopulmonary Syndrome 
7. Hepatocellular carcinoma 
PATHOPHYSIOLOGY OF CHRONIC LIVER DISEASE: 
 Hepatocellular injury due to various etiologies is followed by 
degeneration or necrosis of the hepatocyte. Necrosis leads to kupffer cell 
activation and macrophage immigration. T lymphocytes are also attracted. 
They are stimulated by IL-1. Fibroblasts are also attracted and transformed into 
myofibroblasts, which are responsible for increased synthesis of collagen and 
extra cellular matrix.  
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 Bridging fibrous septa are formed linking portal tracts with one another 
and also with terminal hepatic veins. Fibrosis is the prominent feature of 
progressive damage of the liver. Nodules are formed by cycles of hepatocyte 
scarring and regeneration. The consequent diffuse fibrosis causes disruption of 
the entire architecture of the liver. The histopathological consequence of 
chronic injury and inflammation with formation of fibrosis and nodularity 
surrounded by collagen bands is termed as cirrhosis. 
 This leads to reduced liver mass and impaired hepatocellular function. 
The distorted architecture provides mechanical resistance to normal blood flow 
through liver.  
   
FIGURE 11: HISTOPATHOLOGY OF CIRRHOSIS showing 
architectural distortion and fibrosis with nodular regeneration 
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CLINICAL FEATURES: 
 Chronic liver disease has varied presentations as shown in Table 10. 
Any combination of the features listed may be present in an individual patient. 
Patient can present with weakness, fatigue, anorexia, nausea, vomiting, weight 
loss etc along with typical symptoms of hepatic insufficiency.  
TABLE 10: CLINICAL FEATURES OF CHRONIC LIVER 
DISEASE 
 Jaundice 
 Ascites 
 Spider telengiectasia, palmar 
erythema 
 Loss of libido, hair loss, 
testicular atrophy, 
impotence, 
gynaecomastia(male) breast 
atrophy,  
amennorhea(female) 
 Bruises, purpura, epistaxis 
 Spleenomegaly, variceal 
bleeding 
 Pigmentation , digital 
clubbing. 
 
CAUSES OF CHRONIC LIVER DISEASE: 
Regardless of the etiology, the presentation and complications of 
cirrhosis are basically similar. Still, it is prudent to classify the patients on the 
basis of their etiology. Table 11 lists the various causes of chronic liver disease. 
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 Alcoholism 
 Hepatitis B 
 Hepatitis C 
 Autoimmune Hepatitis 
 Nonalcoholic Steatohepatitis 
 Primary Biliary cirrhosis 
 Cardiac cirrhosis 
 Primary sclerosing 
cholangitis 
 Wilson’s Disease 
 Hemochromatosis 
 Cryptogenic Cirrhosis 
 
TABLE 11: CAUSES OF DECOMPENSATED CHRONIC LIVER 
DISEASE 
COMPLICATIONS: 
 The disease course of chronic liver disease is complicated when signs of 
decompensation develops. These complications occur in all cases regardless of 
the underlying etiology. Table 12 illustrates the various complications that 
occur following decompensation. 
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1. PORTAL HYPERTENSION 
 Gastroesophageal varices 
 Portal hypertensive 
gastropathy 
 Spleenomegaly 
 Ascites, Spontaneous 
Bacterial Peritonitis 
2. HEPATIC 
ENCEPHALOPATHY 
3. HEPATORENAL 
SYNDROME- TYPE I and II 
4. HEPATOPULMONARY 
SYNDROME 
5. PORTOPULMONARY 
HYPERTENSION 
6. MALNUTRITION 
7. COAGULOPATHY 
 FACTOR DEFICIENCY 
 THROMBOCYTOPENIA 
 FIBRINOLYSIS 
8. HEMATOLOGIC 
ABNORMALITIES 
9. BONE DISEASE 
 
TABLE 12: COMPLICATIONS OF DCLD 
PORTAL HYPERTENSION(PH) 
Portal Hypertension is said to be present when the hepatic venous 
pressure gradient is more than 5 mmHg. It is caused due to the following 
mechanisms, 
1. Resistance to passage of blood through liver due to cirrhotic changes 
2. Dilatation of splanchnic vascular bed causing increased splanchnic 
blood flow 
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Portal hypertension account for two most common complications of 
chronic liver disease, Ascites and variceal hemorrhage. Endothelial dysfunction 
occurs in the hepatic circulation due to decreased Nitric Oxide(NO) production. 
Also, NO is consumed as a result of oxidative stress of cirrhosis. Increased 
splanchnic blood flow leads to relative hypovolemia which causes renal 
vasoconstriction and activates renin-angiotensin pathway. This leads to 
retention of sodium and water. Increased blood flow in portal system is 
diverted through portosystemic collaterals leading to development of 
intraabdominal varices. 
 Bleeding is the important complication of varices. Long term survival of 
patients with variceal bleeding is poor and it also depends on the severity of 
underlying hepatic pathology. 
ASCITES: 
It is a common presentation in patients with decompensation. The 
mechanism of development of ascites is attributed to increased splanchnic 
blood flow, reduced renal blood flow leading to activation of renin-angiotensin 
pathway and retention of sodium and water. Initially, as a result of decreased 
effective arterial blood volume, cardiac output is increased. As the disease 
progresses, systemic hypotension develops leading on to activation of multiple 
vasoconstrictor and anti natriuretic hormones in order to maintain homeostasis. 
As a result of hypoalbuminemia, oncotic pressure is decreased and fluid 
leakage occurs across the capillaries into peritoneal cavity. In the advanced 
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state, renal excretion of free water is decreased as a result of vasoconstriction 
and ADH activation as a result of perceived hypovolemia leading on to 
Dilutional Hyponatremia(DH). 
SPONTANEOUS BACTERIAL PERITONITIS(SBP): 
 It is a common and severe complication of ascites. It is caused by 
spontaneous infection of the ascitic fluid. Bacterial translocation has been 
thought to be the reason for the development of SBP. Gut flora is assumed to 
traverse the intestine and reach mesenteric lymph nodes leading to bacteremia 
and seeding of ascitic fluid. It can occur in upto 30% of patients having ascites 
that is severe enough to require admission with a mortality rate of 25%. 
Diagnosis is made by an ascitic fluid neutrophil count of greater than 250. They 
present with fever, altered mental status, abdominal discomfort and elevated 
white blood cell count.  
HEPATORENAL SYNDROME(HRS): 
Functional renal failure without renal pathology occurring in patients 
with cirrhosis is termed Hepatorenal syndrome. Marked disturbances in renal 
circulation in the form of increased vascular resistance together with decreased 
systemic vascular resistance is thought to be the reason for development of 
HRS. The exact reason for renal vasoconstriction is thought to be multifactorial 
and poorly understood. Diagnosis of HRS is made in patients with large 
amount of ascites and a step-wise rise in serum creatinine. Two forms of HRS 
exist that affect 10% of patients with cirrhosis.  
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 Type I HRS is associated with rapid deterioration of renal function with 
doubling of serum creatinine within a two week period. It is often precipitated 
by acute events such as SBP. The median time of survival without treatment in  
type I HRS is one month. Type II HRS is associated with slow decline in renal 
function that may lead on to refractory ascites. 
HEPATIC ENCEPHALOPATHY: 
 Alteration in mental status and cognitive function in persons with 
hepatic failure is termed as hepatic encephalopathy. It is a serious complication 
of chronic liver disease. Neurotoxins derived from gut are not cleared by liver 
because of vascular shunting and decreased hepatic mass. They accumulate in 
brain to cause hepatic encephalopathy. Although ammonia levels are typically 
elevated in hepatic encephalopathy, correlation between ammonia levels and 
severity of liver disease is poor. Other substances implicated in hepatic 
encephalopathy are certain false neurotransmitters and mercaptans.  
 Encephalopathy in patients with liver disease is precipitated by factors 
such as infection, electrolyte disturbance, increased dietary protein load etc., 
clinical presentation may vary from inattention to coma. The pathology in brain 
may vary from edema to herniation. Hepatic Encephalopathy is graded by West 
Haven Criteria, shown in Table 13. 
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GRADE CRITERIA 
GRADE I Trivial lack of awareness ; Shortened attention span; Euphoria 
or anxiety; Impaired performance of addition 
GRADE II Lethargy or apathy; Subtle personality change; Minimal 
disorientation for time or place;  Inappropriate behaviour; 
Impaired performance of subtraction 
GRADE III Somnolence to semi-stupor, but responsive to verbal stimuli; 
Gross disorientation ;Confusion  
GRADE IV Coma (unresponsive to verbal or noxious stimuli) 
 
TABLE 13: WEST HAVEN CRITERIA 
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DYSNATREMIAS IN DECOMPENSATED CHRONIC LIVER 
DISEASE 
Hyponatremia is a frequent complication in patients with 
decompensated liver disease. It occurs due to the impaired free water clearance 
by renal tubules that leads to disproportionate retention of water when 
compared with sodium. This leads to reduction in serum sodium and 
hypoosmolality. Although hyponatremia in decompensated liver disease was 
described 50 years ago, interest in this area increased when studies done in 
1980s indicated that hyponatremia is significant prognostic indicator. 
 Recent studies also showed that presence of hyponatremia is associated 
not only with poor outcome in patients who has not undergone transplants but 
also in post transplant patients.  
HYPONATREMIA: 
 Although hyponatremia in general population is defined as the 
concentration of serum sodium less than 135 mEq/L, in patients with chronic 
liver disease and ascites, it is defined as serum sodium less than 130 mEq/L. 
Still, patients with serum sodium levels between 130 and 135 have pathogenic 
and clinical features almost similar to those with patients who have levels 
below 130 mEq/L. 21.6% of patients with DCLD have serum sodium less than  
130 and 49.4% have levels less than 135 mEq/L.  
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TYPES OF HYPONATREMIA: 
 Patients with decompensated liver disease may develop either 
hypervolemic hyponatremia or hypovolemic hyponatremia. 
Hypervolemic Or Dilutional Hyponatremia: 
This is by far the most common type. It occurs in patients with increased 
extracellular fluid and edema. Hyponatremia here is due to impaired ability of 
kidney to excrete free water that results in disproportionate increase in water 
compared to sodium. Renal impairment is frequent but not always present with 
this type. 
Hypovolemic Hyponatremia: 
It is less common and occurs due to loss of fluid, mainly from kidney 
due to enhanced diuresis as a result of diuretic drugs or from gastrointestinal 
tract. It is associated with reduction in plasma volume, absence of ascites or 
edema, signs of dehydration and pre-renal renal failure. These patients show an 
improvement of sodium values after administration of normal saline or by 
increasing quantity of sodium in the diet. 
 Both types can be differentiated on the basis of volume status. In 
hypervolemic hyponatremia, the effective arterial blood volume is reduced in 
spite of the increase in absolute plasma volume owing to the marked dilatation 
of the arterial circulation.  
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PATHOGENESIS OF HYPONATREMIA IN DCLD: 
Patients with decompensated liver disease and ascites have impairment 
in the ability of kidney to excrete solute free water7,46. In some patients, this 
impairment is only moderate and detected by measuring urine volume 
following a water load. These patients can eliminate water normally and 
maintain sodium concentration within normal limits as long as their intake of 
water is within normal range. When the intake of water is increased, these 
patients may develop hyponatremia and hypoosmolality. Figure 11  shows the 
mechanisms of renal water handling in these patients causing hyponatremia. 
 
FIGURE 12: RENAL WATER HANDLING IN CIRRHOSIS 
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 The important determinant of hyponatremia is increased secretion of 
AVP as a result of non-osmotic stimulation following circulatory changes in 
patients with decompensated liver disease.  
 
FIGURE 13: MECHANISM OF AVP SECRETION AND ITS 
EFFECTS 
WATER RETENTION IN DECOMPENSATED LIVER DISEASE: 
 Water loading test is done by administration of 20 ml/kg body weight of 
water over 45 minutes. In normal individuals, water loading causes production 
of maximally dilute urine and increased urine output. In patients with 
compensated non-ascitic chronic liver disease, response to water load is 
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normal. However, in decompensated chronic liver disease patients, solute free 
water clearance is impaired after water load and the kidneys are unable to 
generate hypotonic urine. 
 Various studies have provided evidence that AVP is a major factor 
responsible for water retention in cirrhosis47. In a study of patients with 
cirrhosis and ascites, patients excreting more than 80% of water load over 5 
hours were labelled excretors and those excreting less than 80% were labelled 
nonexcretors. Serum AVP concentrations were measured before and after water 
loading. It was found that although baseline AVP levels of nonexcretors were 
higher than that of excretors, the difference was not significant. However, the 
nonexcretors were unable to suppress the AVP levels as that of excretors after 
water loading and the difference was significant. The study also found a 
significant correlation between plasma AVP level and the percentage of water 
load excreted.  
MECHANISM OF RETENTION OF WATER AND DILUTIONAL 
HYPONATREMIA: 
Decreased Metabolism of AVP: 
 AVP is metabolized in liver and kidney. In patients with altered liver 
function due to chronic liver disease, metabolic clearance rate of AVP is 
decreased and its level increases. This alone does not explain the whole process 
of dilutional hyponatremia, as the increase in AVP levels should exert a 
negative feedback on its release if osmotic factor is alone responsible for the 
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regulation of AVP. The pathogenesis of dilutional hyponatremia is shown in 
figure 14. 
 
FIGURE 14: PATHOGENESIS OF DILUTIONAL 
HYPONATREMIA 
Reduced Renal Prostaglandins: 
 Renal prostaglandins play a significant role in the balance between 
vasoconstrictor and vasodilator forces on the renal hemodynamics. This is 
particularly important in pathologic conditions such as decompensated liver 
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disease where vasoconstrictor forces predominate. Prostaglandins that cause 
vasodilatation such as PG I2, PG E2 are important to antagonize the effects of 
vasoconstrictors such as angiotensin, AVP, norepinephrine and increased 
sympathetic tone. In patients with decompensated liver disease, 
cyclooxygenase inhibition has been found to have a deleterious effect on renal 
hemodynamics with a decrease in renal blood flow and GFR. It has been found 
that prostaglandins inhibit AVP mediated water reabsorption48. These 
observations suggest that impairment of renal hemodynamics and reduced 
synthesis of prostaglandins such as PGE2, PG I2 together cause reduced free 
water excretion.  
Decreased Distal Tubule Delivery: 
Another mechanism proposed for impaired free water excretion is 
decreased delivery of the filtrate to the distal segment of the nephron. Lithium 
clearance, which is used to estimate delivery of filtrate to distal segment, is 
reduced in patients with decompensated liver disease with ascites49. It is also 
thought that this decreased delivery of sodium to distal tubules is responsible 
for impaired aldosterone escape and atrial natriuretic peptide resistance in 
decompensated liver disease and ascites50.  
Non Osmotic Release Of AVP: 
In patients with hyponatremia and hypoosmolality, AVP release would 
be suppressed. The most reasonable explanation for raised AVP levels in 
decompensated patients would be non osmotic release of AVP. Anderson et 
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al51 found that acute increase of portal vein pressure is associated with 
antidiuresis in dogs. Arterial vasodilatation which is characteristic of 
decompensated liver disease causes decreased EABV, which stimulates 
baroreceptors leading to non-osmotic secretion of AVP along with activation of 
antidiuretic and vasopressor systems52. This neurohormonal response is 
transient and occurs at the expense of increased plasma volume during the early 
stages of disease. As the disease progresses, the neurohormonal response 
cannot compensate for the arterial underfilling and leads to sodium and water 
retention, edema and ascites. 
PROGNOSTIC SCORES: 
The prognostic scores in decompensated liver disease are used for 
various reasons. They help in identifying patients at risk for developing 
complications, to predict the risks involved in various procedure such as porto-
systemic shunts, to prioritize the patients waiting for Orthotopic Liver 
Transplantation(OLT). 
CHILD- TURCOTTE PUGH SCORE: (CPS) 
 It was developed in 1964 by Child and Turcotte. It consisted of serum 
bilirubin, albumin, ascites, clinically apparent encephalopathy and 
malnutrition53. Each variable was given points according to the severity or cut-
off ranges. The combined score is classified in to three groups of worsening 
severity(A,B,C). A modification of this score was put forward by Child-Pugh 
ten years later to predict outcome from surgical procedures used to reduce PH 
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and treat esophageal varices54. In the modified CPS, Prothrombin Time or 
International Normalized Ratio(INR) was included in the place of nutritional 
status and the lowest cut-off for albumin was reduced to 2.8mg/dl. Later, this 
score was used to predict the likelihood of survival in patients with cirrhosis. 
Table 14 shows the modified CPS.  
TABLE 14: MODIFIED CPS 
VARIABLE POINTS 
1 2 3 
Serum 
Bilirubin(mg/dl) 
<2 2-3 >3 
Serum 
Albumin(mg/dl) 
>3.5 2.8-3.5 <2.8 
INR <1.7 1.7-2.2 >2.2 
Ascites None Mild Moderate to 
Severe 
Encephalopathy None Grade I-II Grade III-IV 
Class A- 5-6 points; Class B- 7-9 points; Class C- 10-15 points 
MELD SCORE: (The Model for End-stage Liver Disease) 
It was initially developed to assess the likelihood of survival in patients 
with refractory ascites and undergoing Transjugular Intrahepatic Porto-
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systemic shunt(TIPPS)55. Later, it was found to be helpful in ascertaining the 
prognosis and to prioritize patients for receipt of liver transplant.56,57 United 
Network for Organ Sharing and Eurotransplant are using this score to prioritize 
patients for liver transplant.57,58 
Initially MELD was calculated using the following variables: Bilirubin, 
Creatinine, INR and cause of cirrhosis. These four variables independently 
predicted survival in patients undergoing TIPPS in a multivariate Cox model. 
MELD score = 9.6 loge (creatinine mg/dl) + 3.8 loge (bilirubin mg/dl) + 11.2 
loge INR + 6.4 (cause of cirrhosis; 0 = cholestatic/alcohol, 1 = other) 
Kamath et al found that the three month mortality rate predicted by 
MELD was similar across various cohorts of cirrhotic patients. Further, it was 
shown that eliminating the last variable did not alter the ability of score to 
predict prognosis. The present score is calculated by, 
MELD = 3.78[loge serum bilirubin (mg/dl)] + 11.2[loge INR] + 9.57[loge 
serum creatinine (mg/dl)] + 6.43 
POINTS TO BE REMEMBERED WHILE CALCULATING THE 
SCORE: 
 The score ranges from 6-40 and any value more than 40 is taken as 40. 
 It is used in patients 12 years and older. 
 Maximum value for creatinine is 4. If patient is dialysed twice in the 
preceding week, creatinine value is taken as 4.  
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 If the value of a variable is less than one, it is taken as one.(Serum 
bilirubin value of 0.9 is taken as 1) 
SERUM SODIUM AS A PROGNOSTIC MARKER: 
The prognostic effect of serum sodium has been studied in patients with 
decompensated liver disease. A large study done on patients admitted for 
cirrhosis, has shown that the prevalence of hyponatremia to be 29.8%.59 Low 
serum sodium levels were found to be an indicator of poor prognosis and short 
term in-hospital mortality. Low serum sodium levels were not found to be an 
independent predictor of mortality when compared with CPS.60 Biggins et al 
showed that the ability of MELD score to predict three month waiting list 
mortality improved when serum sodium was added to it.61 The mortality risk 
for patients with decompensated liver disease was found to be higher in 
patients with hyponatremia irrespective of the disease severity.62 
HYPERNATREMIA IN DCLD: 
 Although hypernatremia is less common than hyponatremia in 
decompensated liver disease, Sanford E.Warren et al found that patients with 
hypernatremia and decompensated liver disease had a mortality of 87% and 
attributed the cause of hypernatremia to decreased water intake due to 
encephalopathy and osmotic cathartics usage.16 
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MATERIAL AND METHODS 
SOURCE OF STUDY: 
The study will be conducted on consecutive patients admitted with 
DCLD in Medical Wards (Male and Female) in Government Vellore Medical 
College and Hospital during the study period of one year from August 2014- 
July 2015. 
METHOD OF COLLECTION OF DATA: 
Ethical Committee clearance obtained from Institution. Informed 
consent was obtained from the patients enrolled in the study. The data of the 
patients were collected using a proforma. The first section of the proforma 
contains patient’s demographic profile with detailed history. The second 
section contains detailed clinical examination that will be carried out at the 
time of admission. The third section contains investigations that were done to 
aid the diagnosis and the serum sodium level.  
Patients were selected based on history, examination, laboratory 
investigations and imaging suggestive of the diagnosis of Decompensated 
Chronic Liver Disease. The presence of various complications and the outcome 
of the patients were monitored. The severity of the disease was calculated using 
MELD score and Child Pugh Score. Ascites was classified in to three grades: 
Grade I- presence on examination not clear, but observed in imaging; Grade II-  
easily made out examination and palpation; Grade III- severe abdominal 
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distension requiring large volume paracentesis. Hepatic Encephalopathy was 
graded using West Haven Criteria.  
INCLUSION CRITERIA: 
All patients with Decompensated Chronic Liver Disease diagnosed by 
examination, laboratory investigations and radiological imaging. 
EXCLUSION CRITERIA: 
1. Patients with cardiac failure 
2. Patients with chronic kidney disease 
3. Patients on drugs such as SSRIs, TCA, MAO inhibitors, cytotoxic drugs 
etc., 
STATISTICS: 
 The collected data were entered in a Microsoft Excel Sheet. Graphs and 
tables were generated using Microsoft Word and Microsoft Excel. Statistical 
analysis were done using medcalc 15.8, Minitab 17, IBM SPSS 22. 
Quantitative data was analysed using Mean, Median, Mode and Standard 
Deviation(SD). Qualitative data was analysed using Chi Square Test, One way 
ANOVA and Fisher’s test. Difference between two variables is considered 
significant when ‘p’ value is less than 0.05. 
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     RESULTS 
 Data were collected from 97 patients admitted in our hospital. The mean 
age of the patients was 49.69 years with a range of 28-70 years. Out of the 97 
patients, 91(93.81%) were males and 6(6.19%) were females. Table 15 shows 
the demographic details and causes of DCLD. 
   TABLE 15: DEMOGRAPHY DETAILS 
Sl.No Parameter No Of Patients % Of Patients Mean SD 
1. Age 97 
 
49.69 10.26 
2. Gender 
    
 
Male 91 93.81% 
  
 
Female 6 6.19% 
  
3. Cause of cirrhosis 
    
 
Alcohol 89 91.75% 
  
 
HBV 7 7.22% 
  
 
HCV 1 1.03% 
  
 
Other 0 0.00% 
  
4. MELD score 
  
13.54 5.50 
5. Serum sodium 
  
134.18 5.02 
 
1) ≤130 meq/L 23 23.71% 
  
 
2) 131-135 meq/L 32 32.99% 
  
 
3) ≥136 meq/L 42 43.30% 
  
 
4)>145 0 0% 
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Alcoholic liver disease was the commonest cause of DCLD in this study 
accounting for  91.75% while chronic hepatitis B and hepatitis C was found to 
be the causative factor in 7.22% and 1.03% respectively. The mean 
concentration of sodium of all patients was 134.18 with a range of 120-144. 
Based on the serum sodium levels, 23.71% of patients had serum sodium levels 
less than or equal to 130. 32.99% of patients had serum sodium levels between 
131 and 135, while 43.3% of patients had serum sodium levels ≥136. No 
patients presented with serum sodium greater than 145. The mean MELD score 
was found to be 13.54 with a range of 7.5- 33.7 . 
Ratio of male and female in this study was 15.2:1. 
FIGURE 15: BAR DIAGRAM SHOWING GENDER 
DISTRIBUTION
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Alcohol was the most common cause of DCLD in this study followed by 
chronic hepatitis B and chronic hepatitis C. 
FIGURE 16: PIE CHART SHOWING ETIOLOGY OF 
DCLD
 
43.3% of patients had serum sodium levels ≥136. 32.99% of patients 
had serum sodium levels between 131 and 135 while 23.71% of patients had 
serum sodium levels less than or equal to 130.(Figure 16) 
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FIGURE 17: BAR DIAGRAM SHOWING DISTRIBUTION OF 
PATIENTS BY SERUM SODIUM CONCENTRATION 
 
Patients were classified into three groups based on the serum sodium 
level to assess the association between serum sodium levels and patient 
characteristics, complications and severity of disease as calculated by MELD 
score and CPS. Those with serum sodium levels less than or equal to 130 
formed one group while those with serum sodium levels between 131-135 and 
those with ≥136 were the other two groups. Mean age of patients with sodium 
levels  ≤130 was 50.50+11.08, while in those with serum sodium levels 131-
135 and ≥136 were 49.11+11.49 and 50.82+10.67 respectively. No statistical 
difference was found among the three groups. (p value - 0.877).  
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TABLE 16: CHARACTERISTICS OF PATIENTS ACCORDING 
TO SERUM SODIUM CONCENTRATION 
Sl 
No PARAMETERS 
≤130      
meq/L 
131-135 
meq/L 
≥136 
meq/L P value 
  N=23 N=32 N=42 
1 
Age(years) (Mean 
+SD) 50.50+11.08 
49.11  
+11.49 
50.82+10.
67 
  
0.877* 
  2 
SEX: 
Male 
Female 
22 
1 
31 
1 
38 
4 0.479$ 
  3 
CAUSE OF DCLD: 
Alcohol 
HBV 
HCV 
Others 
20 
3 
0 
0 
31 
1 
0 
0 
38 
3 
1 
0 0.376$ 
  4 
MELD score (Mean 
+SD) 18.89+6.70 13.17+4.40 
10.90+2.9
5 
<0.000
1* 
  5 Child-Pugh Score 10.00 +1.86 8.53+1.27 
7.48 
+1.33 
<0.000
1* 
  6 
Child Pugh Class 
Class A 
Class B 
Class C 
0 
11 
12 
1 
24 
7 
9 
29 
4 
<0.000
1$ 
*- calculated using one way annova; $- calculated using chi square test.  
Serum sodium levels had a strong association with severity of disease as 
calculated by Child Pugh Class. Among those with serum sodium levels ≤130, 
11 belonged to class B and 12 belonged to class C. Among patients with serum 
sodium levels between 131-135, 1 belonged to class A, 24 belonged to class B 
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and 7 belonged to class C. Among patients with serum sodium levels ≥136, 9 
belonged to class A, 29 belonged to class B and 4 belonged to class C.(p value 
<0.0001) 
Patients with serum sodium levels ≤130 had a mean MELD score of 
18.89+6.70, while those with levels between 131-135 and ≥136 had mean 
scores of 13.17+4.40 and 10.90+2.95 respectively. The difference in MELD 
scores among the three groups was statistically significant. (p value <0.0001) 
No statistical difference was found among the three groups with respect 
to gender and causative factor.(p value – 0.479, 0.376 respectively). Figure 17 
shows the gender distribution among the three groups. 
FIGURE 18: BAR DIAGRAM SHOWING GENDER 
DISTRIBUTION ACCORDING TO SERUM SODIUM 
CONCENTRATION 
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FIGURE 19: BAR DIAGRAM SHOWING CAUSE OF DCLD 
ACCORDING TO SERUM SODIUM CONCENTRATION 
 
Alcohol remains the common cause of DCLD among the three groups 
followed by chronic hepatitis B as shown in Figure 18.  
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TABLE 17: CLINICAL PRESENTATION OF PATIENTS AT THE 
TIME OF ADMISSION 
SL. 
NO. CLINICAL PRESENTATION 
NUMBER Of 
PATIENTS 
% Of 
PATIENTS 
1 Abdominal Distension 97 100.00% 
2 Lower Limb Swelling 97 100.00% 
3 Jaundice 29 29.90% 
4 Altered Sensorium 14 14.43% 
5 Gastrointestinal Bleeding 19 19.59% 
 
All patients presented with abdominal distension and lower limb 
swelling at the time of admission, while clinically detectable jaundice was 
found in around 30% of patients. Around 20% of patients presented with GI 
bleeding while 14 patients presented with history of altered sensorium. 
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Figure 19 shows the clinical presentation of patients at the time of 
admission. Abdominal distension and lower limb swelling were the most 
common presenting complaints followed by jaundice, GI bleeding and altered 
sensorium. 
FIGURE 20: BAR DIAGRAM SHOWING CLINICAL 
PRESENTATION OF PATIENTS 
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TABLE 18: FREQUENCY OF COMPLICATIONS 
SL 
NO COMPLICATIONS 
NUMBER OF 
PATIENTS 
% OF 
PATIENTS 
1 Ascites 97 100.00% 
2 Portal Hypertension 92 94.85% 
3 
Hepatic 
Encephalopathy 17 17.53% 
4 GI Bleeding 19 19.59% 
5 Coagulopathy 12 12.37% 
6 
Hepatorenal 
Syndrome 11 11.34% 
7 SBP 12 12.37% 
 
 Among the 97 patients, Ascites was present in all the patients while 
portal hypertension was present in around 95% of patients. Hepatic 
encephalopathy was present in 17.53% while GI bleeding was found in 19.59% 
of patients. Coagulopathy and SBP were found in 12.37% patients, while 
hepatorenal syndrome was found in 11.34%. 
 
 
78 
 
In the present study, Ascites was the most common complication 
while hepatorenal syndrome is the least, as shown in the figure 20. 
FIGURE 21: BAR DIAGRAM SHOWING DISTRIBUTION 
OF COMPLICATIONS 
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TABLE 19: FREQUENCY OF COMPLICATIONS BY SERUM 
SODIUM CONCENTRATION 
Sl No. COMPLICATIONS 
≤130 meq/L 
Number 
(%) 
131-135meq/L 
Number(%) 
≥136 
meq/L 
Number 
(%) 
p value* 
1 Ascites 23(100%) 32(100%) 42(100%) 0.51 
2 Portal Hypertension 23(100%) 32(100%) 37(88.10%) 0.031 
3 Hepatic Encephalopathy 13(56.52%) 4(12.50%) 0(0%) <0.0001 
4 GI Bleeding 9(39.13%) 7(21.88%) 3(7.14%) 0.0074 
5 Coagulopathy 7(30.43%) 2(6.25%) 3(7.14%) 0.0106 
6 Hepatorenal Syndrome 11(47.83%) 0(0%) 0(0%) <0.0001 
7 SBP 8(34.78%) 4(12.50%) 0(0%) 0.0002 
 *- calculated by chi square test. 
There was significant difference in the occurence of complications of 
DCLD such as Portal Hypertension (p value- 0.031), Hepatic 
Encephalopathy(p value <0.0001), GI Bleeding(p valuve- 0.0074), 
coagulopathy(p value- 0.0106), hepatorenal syndrome(p value<0.0001), SBP(p 
value- 0.0002)among the three groups. There was no significant difference in 
the presence of ascites among the three groups(p value- 0.51) 
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Figure 21 shows the increased occurrence of complications in patients 
with lower serum sodium levels. 
FIGURE 22: FREQUENCY OF COMPLICATIONS ACCORDING 
TO SERUM SODIUM CONCENTRATION 
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TABLE 20: COMPARISION OF COMPLICATIONS ACCORDING 
TO SERUM SODIUM CONCENTRATION 
Sl 
No 
 
COMPLICATION 
 
≤130 meq/L 
N=23 
ODDS 
RATIO 
(95%CI) 
 
P 
Value* 
131-
135meq/L 
N=32 
ODDS 
RATIO 
(95% CI) 
 
P 
value* 
1 Ascites 
0.5529 
(0.0106 to 
28.7818) 1 
0.7647 
(0.0148 to 
39.5772) 1 
2 
Portal 
Hypertension 
6.8933 
(0.3642 to 
130.4817) 0.152 
9.5333 
(0.5075 to 
179.068) 0.0653 
3 
Hepatic 
Encephalopathy 
109.2857 
(5.9987 to 
1990.979) <0.0001 
13.4211 
(0.6954 to 
259.0198) 0.0312 
4 GI Bleeding 
8.3571 
(1.9755 to 
35.3548) 0.0026 
3.6400 
(0.8601 to 
15.4055) 0.0900 
5 Coagulopathy 
5.6875 
(1.3046 to 
24.7955) 0.0265 
0.8667 
(0.1361 to 
5.5199) 1 
6 
Hepatorenal 
Syndrome 
78.2000 
(4.2991 to 
1422.437) <0.0001 
1.3077 
(0.0253 to 
67.6793) 1 
7 SBP 
46.6129 
(2.5370 to 
856.4415) <0.0001 
1.3077 
(0.0253 to 
67.6793) 0.0312 
*- calculated by fisher’s test. 
When compared to patients with serum sodium levels ≥136, patients 
with serum sodium levels ≤130 had a significantly increased risk for 
complications: 109.29 for Hepatic Encephalopathy(p value <0.0001), 8.36 for 
GI bleeding(p value = 0.0026), 5.69 for Coagulopathy(p value = 0.0265), 78.2 
for Hepatorenal syndrome(p value <0.0001) and 46.61 for SBP(p value 
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<0.0001). Ascites and portal hypertension did not have statistical difference 
and increased risk.(p value – 1, 0.152 respectively) 
When compared to patients with serum sodium levels ≥136, patients 
with serum sodium levels between 131 and 135 had a significantly increased 
risk for complications: 13.42 for Hepatic Encephalopathy(p value- 0.0312); 
1.3077 for SBP (p value- 0.0312). Other complications did not have statistical 
difference among the two groups. 
TABLE 21: MORTALITY ACCORDING TO SERUM SODIUM 
CONCENTRATION 
≤130 
meq/L(N=23) 
131-135 
meq/L(N=32) 
≥136 
meq/L(N=42) 
P 
value 
Mortality 7(30.4%) 2(6.25%) 0(0%) 0.0002 
 
 Among 23 patients with serum sodium levels ≤130, 7 patients(30.4%)  
died. Among 32 patients with serum sodium levels between 131 and 135, 2 
patients(6.25%) died. There were no deaths among patients with sodium levels 
≥136. The difference in mortality among these three groups was statistically 
significant. (p value- 0.0002) 
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Figure 22 shows that mortality increases as serum sodium levels decreases. 
FIGURE 23: MORTALITY ACCORDING TO SERUM SODIUM 
CONCENTRATION 
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DISCUSSION 
A significant proportion of patients with DCLD have abnormal serum 
sodium concentration. Hyponatremia is the most common occurrence in our 
study. No patients presented with serum sodium levels greater than 145. 
 56.7% of patients had serum sodium levels less than 135, while 23.71% 
patients had serum sodium levels than 130. Serum sodium levels less than 120 
were uncommon. 
TABLE 22: COMPARISON OF VARIOUS STUDIES 
SHOWING DISTRIBUTION OF PATIENTS ACCORDING TO 
SERUM SODIUM LEVELS 
STUDIES 
DISTRIBUTION OF PATIENTS 
≤130 mEq/L 131-135 mEq/L ≥136 mEq/L 
PRESENT STUDY 23.71% 32.99% 43.3% 
ANGELI P ET AL 21.6% 27.8% 50.6% 
JONG HOON KIM 
ET AL 27.1% 20.8% 52.1% 
SHAIKH ET AL 26.7% 24.9% 48.4% 
BORRONI ET AL 29.8%   
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Angeli P et al8 collected data of 997 cirrhosis patients from 28 
hepatology departments across Europe, Asia, North America and South 
America. Her study revealed that 50.6% patients had normal serum sodium 
levels, 27.8% patients had sodium levels between 131-135 mEq/L and 21.6% 
patients had serum sodium levels less than or equal to 130 mEq/L.  
Jong Hoon Kim et al63 analyzed 188 patients admitted in Ilsan paik 
hospital, Korea with complications of cirrhosis and found that 52.1% patients 
had normal serum sodium levels, while 20.8% patients had serum sodium 
levels between 131 and 135. 27.1% patients had serum sodium levels less than 
or equal to 130.  
Shaikh et al64 studied 217 patients with cirrhosis and found that 48.4% 
patients had serum sodium levels more than 135 mEq/L, while 24.9% patients 
had serum sodium levels between 131-135 mEq/L. 26.7% patients had serum 
sodium levels less than or equal to 130 mEq/L. 
Borroni et al59 studied 156 patients admitted with cirrhosis and found 
that 29.8% patients had serum sodium levels less than or equal to 130 mEq/L. 
The results of the present study extend the observations made by the 
above mentioned studies that decompensated liver disease is associated with 
abnormal serum sodium concentration. It also shows that hyponatremia is the 
common abnormality with more than half of the patients having serum sodium 
levels less than 135 mEq/L.  
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Various studies have established that lower sodium levels were 
associated with ascites that are difficult to manage with diuretics and requiring 
frequent large volume paracentesis. Arroyo et al noted that patients having 
serum sodium less than 130 mEq/L had a relatively low GFR and subsequently 
decreased free water clearance. These patients responded poorly to diuretics 
when compared with those who had sodium levels more than 130 mEq/L. 
Angeli P et al and Bernardi et al65 also found that poorer response to diuretics 
was associated with lower serum sodium concentration compared to patients 
who showed response to diuretics. The present study also found that patients 
with lower sodium levels had higher grade of ascites. 
Angeli P et al found that 38% of patients who had serum sodium levels 
less than or equal to 130 mEq/L had Hepatic Encephalopathy compared to 24% 
with serum sodium levels between131 and 135 mEq/L. 
Jong Hoon Kim et al found that  43.1% of patients with serum sodium 
levels less than or equal to 130 mEq/L developed hepatic encephalopathy 
compared to 35.8% with serum sodium levels between 131 and 135 mEq/L. 
 Shaikh et al found that 25.8% of patients who had serum sodium levels 
less than or equal to 130 mEq/L developed hepatic encephalopathy.  
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TABLE 23: COMPARISION OF STUDIES SHOWING 
ASSOCIATION BETWEEN SERUM SODIUM 
CONCENTRATION AND HEPATIC ENCEPHALOPATHY. 
STUDIES 
FREQUENCY OF HEPATIC 
ENCEPHALOPATHY 
≤130 mEq/L 131-135 mEq/L ≥136 mEq/L 
PRESENT STUDY 56.52% 12.50% 0.00% 
ANGELI P ET AL 38% 24% 15% 
JONG HOON KIM 
ET AL 43.1% 35.8% 24.4% 
SHAIKH ET AL 25.8%   
 
 In the present study, patients with serum sodium levels ≤130 
mEq/L  had increased frequency of hepatic encephalopathy compared to 
the other two groups. 
 Angeli P et al found that 17% of patients with serum sodium levels 
≤130 mEq/L had hepatorenal syndrome compared to 10% and 6% in 
patients with serum sodium levels 131-135 mEq/L and more than 135 
mEq/L respectively. 
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 Jong Hoon Kim et al reported that that 3.9% of patients with serum 
sodium levels ≤130 mEq/L had hepatorenal syndrome compared to 2.5% 
and 3% in patients with serum sodium levels 131-135 mEq/L and more 
than 135 mEq/L respectively. 
TABLE 24: COMPARISION OF STUDIES SHOWING 
ASSOCIATION BETWEEN SERUM SODIUM 
CONCENTRATION AND HEPATORENAL SYNDROME. 
STUDIES 
FREQUENCY OF HEPATORENAL SYNDROME 
≤130 mEq/L 131-135 mEq/L ≥136 mEq/L 
PRESENT STUDY 47.83% 0% 0% 
ANGELI P ET AL 17% 10% 6% 
JONG HOON KIM 
ET AL 
3.9% 2.5% 3% 
 
 In present study, patients with serum sodium levels less than or equal to 
130 mEq/L had increased frequency of hepatorenal syndrome compared to 
other two groups. 
 Angeli P et al found that low sodium level was associated with increased 
frequency of spontaneous bacterial peritonitis. 
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 Jong Hoon Kim et al reported that that 33.3% of patients with serum 
sodium levels ≤130 mEq/L had SBP compared to 30.7% and 16.3% in patients 
with serum sodium levels 131-135 mEq/L and ≥136 mEq/L respectively. 
 The present study also lends support to the above observations. 34.78% 
of patients with serum sodium levels ≤130 mEq/L had SBP compared to 12.5% 
of patients with serum sodium levels between 131-135 mEq/L. 
TABLE 25: COMPARISION OF STUDIES SHOWING 
ASSOCIATION BETWEEN SERUM SODIUM 
CONCENTRATION AND SBP 
STUDIES 
FREQUENCY OF SBP 
≤130 mEq/L 131-135 mEq/L ≥136 mEq/L 
PRESENT STUDY 34.78% 12.5% 0% 
JONG HOON KIM 
ET AL 33.3% 30.7% 16.3% 
 
 Angeli P et al, Jong Hoon Kim et al and Shaikh et al found no 
association between GI bleeding and sodium levels. The present study showed 
increased frequency of GI bleeding in patients with low sodium levels. 
 Sanford E.Warren et al reported that 15 out of 25 patients with 
decompensated liver disease had hypernatremia in their study. The present 
study had no patients with serum sodium levels more than 145 mEq/L. 
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 Jong Hoon Kim et al found that lower sodium levels were associated 
with increased MELD score and Child Pugh score. This indicates that lower 
serum sodium levels were associated with severe disease. 
 The present study also showed that patients with sodium levels ≤130 
mEq/L had higher MELD score and Child Pugh Score compared to other two 
groups.  
TABLE 26: COMPARISION OF STUDIES SHOWING 
ASSOCIATION BETWEEN SERUM SODIUM 
CONCENTRATION AND MELD SCORE 
STUDIES 
MELD SCORE 
≤130 mEq/L 131-135 mEq/L ≥136 mEq/L 
PRESENT STUDY 18.89+6.70 13.17+4.40 10.90+2.95 
JONG HOON KIM 
ET AL 17.20+5.10 16.30+5.20 13.90+ 4.60 
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TABLE 27: COMPARISION OF STUDIES SHOWING 
ASSOCIATION BETWEEN SERUM SODIUM 
CONCENTRATION AND CPS 
STUDIES 
CHILD PUGH SCORE(CPS) 
≤130 mEq/L 131-135 mEq/L ≥136 mEq/L 
PRESENT STUDY 10.00 +1.86 8.53+1.27 7.48 +1.33 
JONG HOON KIM 
ET AL 10.50+1.60 9.80+1.70 8.10+ 1.60 
 
 The present study also shows increased mortality among patients 
with lower sodium levels. 
TABLE 28: MORTALITY AND SERUM SODIUM 
SERUM SODIUM MORTALITY 
≤130 mEq/L 30.4% 
131-135 mEq/L 6.25% 
≥136 mEq/L 0% 
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SUMMARY OF RESULTS 
 The study was conducted on 97 patients admitted with DCLD in 
medical wards in Government Vellore Medical College. 
 Alcohol is the most common etiology of DCLD in this study followed 
by Hepatitis B. 
 Hyponatremia is the most common sodium abnormality(56.7%). No 
patients presented with hypernatremia. 
 Patients were divided into three groups based on serum sodium; those 
with serum sodium levels ≥136 mEq/L comprised one group while those 
with 131-135 mEq/L and ≤130 mEq/L formed the other two groups.  
 Serum sodium level was not associated with gender or etiology of 
DCLD. 
 There was significant difference in occurrence of complications such as 
Portal Hypertension(p value – 0.031), Hepatic Encephalopathy(p value 
<0.0001), Hepatorenal Syndrome(p value <0.0001), Spontaneous 
Bacterial Peritonitis(p value-0.0002), Coagulopathy(p value- 0.0106). 
Increased frequency of complications was noted among patients with 
lower serum sodium levels. 
  There was significant difference in severity scores such as MELD and 
CPS among the three groups. 
 There was significant difference in mortality among the three groups(p 
value-0.0002). Patients with lower sodium levels had increased 
mortality. 
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CONCLUSION 
Decompensated Chronic Liver Disease is associated with abnormal 
serum sodium concentration. Hyponatremia is the most common abnormality 
in this study. Age, gender and cause of DCLD did not have any association 
with serum sodium levels. Serum sodium levels less than 135 mEq/L is 
associated with increased frequency of complications such as Hepatic 
Encephalopathy, Hepatorenal Syndrome, Spontaneous Bacterial Peritonitis and 
GI Bleeding when compared to patients with serum sodium levels ≥136 
mEq/L. Patients with serum sodium concentration less than 130 mEq/L are the 
most affected. Lower serum sodium levels are associated with increased 
MELD score, increased CPS score and increased mortality indicating the 
inverse relationship between serum sodium levels and the severity of disease. 
Thus patients with decreased serum sodium levels should be considered a high 
risk population because of the increased frequency of complications and 
mortality.  
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PROFORMA 
 
A STUDY OF SERUM SODIUM LEVELS IN DECOMPENSATED CHRONIC 
LIVER DISEASE AND ITS CLINICAL CORRELATION 
  
Name:        Age /sex: 
Occupation:       Date of enrollment: 
Address: 
Contact no: 
Presenting complaints:   Yes     No 
Abdominal distension 
Lower limb swelling 
Jaundice 
Bleeding (hematemesis/malena) 
Fever 
Abdominal pain 
Oliguria 
Altered sensorium 
Others 
Past history: 
 H/o Jaundice                           Previous Treatment   
Personal history: 
Alcohol:     Smoking:                            Family H/o: 
  
General physical examination: 
Pulse:                                                   BP: 
RR:                                                      Temp: 
Pallor                             Icterus                                        Edema 
Clubbing                       Cyanosis                                     
Lymphadenopathy 
S/o liver cell failure: 
Alopecia  
Asterixis (Flaps)  
Atrophy of The Testis  
Bitot’s Spot  
Bleeding Tendencies  
Dupuytren’s Contracture  
Jaundice  
Fruity Odour  
Foetor Hepaticus  
Gynaecomastia  
Loss of Buccal Pad of Fat  
Loss of Secondary Sexual 
Characters 
 
Parotid Enlargement  
Palmar Erythema  
Pedal Edema  
Pruritis  
Spider Naevi  
Systemic examination: 
ABDOMEN:   
 Ascites    Liver / spleen   Bowel sounds 
RS:     Added sounds 
CVS:  S1 S2                          MURMUR 
CNS:   Sensorium 
Asterixis 
  
Investigations: 
HB                                           WBC                                  PLATELET 
RBS                                         UREA                                CREATININE 
TB/DB                                    TP/ALB                              AST/ALT 
PT/INR                                   HBsAG                               HCV 
ASCITIC FLUID ANALYSIS: 
CELL COUNT PROTEIN/ SUGAR CULTURE AND SENSITIVITY 
   
USG ABDOMEN: LIVER ASCITES PORTAL VEIN KIDNEY 
    
SERUM ELECTROLYTES: 
 AT THE TIME OF ADMISSION 
 
OUTCOME 
SERUM SODIUM  
 
COMPLICATIONS  
UGI SCOPY: 
 
CHILD PUGH SCORE AND CLASS:                                              MELD SCORE: 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
MASTER  CHART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
                               
  
KEY TO MASTER CHART 
S.N. – Serial Number 
A – Age 
S – Sex 
AD – Abdominal Distension 
LS – Leg Swelling 
JAU – Jaundice 
ASN – Altered Sensorium 
GIB – Gastro Intestinal Bleeding 
ALC – Alcohol 
PAL – Pallor  
ICT – Icterus  
CLU – Clubbing  
PE – Pedal Edema 
LCF – Signs of Liver Cell Failure 
ORG – Organomegaly 
SPL – Spleenomegaly 
AS - Ascites 
PHT – Portal Hypertension 
HE – Hepatic Encephalopathy 
HRS – Hepato Renal Syndrome 
SBP – Spontaneous Bacterial 
Peritonitis 
CGP – Coagulopathy 
Ur – Urea  
Cr – Creatinine  
Na – Serum Sodium  
TB/DB – Total/ Direct Bilirubin 
ALT – Alanine Transaminase 
AST – Aspartate Transaminase 
ALP – Alkaline Phosphatase 
TP/ALB – Total Protein/ Albumin 
PT – Prothrombin Time 
INR – International Normalized 
Ratio 
MELD – Model for End Stage 
Liver Disease Score 
CPS – Child Pugh Score 
CPC – Child Pugh Class 
HBsAg – Hepatitis B Surface 
Antigen 
HCV – Antibody to Hepatitis C 
Virus 
USG ABD – Ultrsonogram 
Abdomen 
O – Outcome 
D – Discharged 
E – Expired 
P – Present 
A – Absent 
NEG -  Negative 
POS – Positive 
PV – Portal Vein 
G - Grade 
 
